admin – Page 4171 – Get News Story

Yaakov Tannenbaum Takes on Brick, NJ Real Estate in Ongoing Growth With Complete Transparency & Cutting-Edge Marketing

Yaakov Tannenbaum is a licensed NJ real estate agent known in the local community as Your Brick Expert.

Yaakov Tannenbaum, a premier real estate expert from Brick, NJ, is taking on the local market with his distinct brand of marketing and expertise.

Also known as Your Brick Expert, Yaakov has combined his marketing style with solid fundamentals, guaranteeing complete transparency and honesty to all clients.

Based on years of experience in the real estate industry, Yaakov firmly believes that the township is due to grow in the wake of the ongoing Monmouth & Ocean County sales surge.

For Tannenbaum, this is not just a hunch, but something he is focusing his business on. This is why Your Brick Expert goes beyond Brick, NJ, and offers homes in Howell, Jackson, Toms River, and more.

The official platform allows users to filter through different areas or use an interactive map to target their ideal location.

Going the extra mile, the website also offers a home price estimate tool, where potential clients can receive a report with multiple estimates, actual sold prices, and even potential buyers.

“My mission is to provide a seamless and stress-free home buying and selling experiences for our clients,” Tannenbaum said, adding that his team prioritizes clear and responsive communication.

“From start to finish, he made the whole process so much easier and stress-free. Yaakov took the time to really understand what I was looking for in a home and worked tirelessly to help me find the right one,” a satisfied customer named Mordechai said in their five-star review of Your Brick Expert.

“His knowledge of the market is top-notch, and he was always available to answer questions or offer guidance whenever I needed it.”

Yaakov himself added, “Our goal is to go above and beyond to guide our clients through each step of the process, making sure they feel heard and supported. We value knowledge, professionalism, and dedication, striving to provide exceptional service that exceeds expectations.”

The real estate agent stresses the importance of putting clients first over and over again, branding such approach the only way to create actual, strong, long-term relationships.

“By embodying these values and delivering exceptional service throughout the home buying journey, we aim to establish ourselves as the go-to real estate agent in the Brick, Toms River, Jackson, NJ area,” Yaakov concluded.

Tannenbaum maintains a presence on social media, where clients and anyone interested in his work can find him on Tik Tok, X, Instagram, and more. The real estate agent hosts various content types of YouTube, ranging from regular house showings to informative and educational clips to highlights from Yaakov’s podcast appearances.

Social media activity is a core component of how Your.Brick Expert operates. Yaakov embraces new forms of communication and gladly takes potential clients on virtual tours while also going on podcasts to discuss his business approach at length.

Creative approach to video marketing is another core component, with Yaakov gladly pushing the envelope of the video format to deliver something unique for every single client or just deliver fun content to the community.

The end result is that both sides are happy, Mr. Tannenbaum pointed out, explaining how transparency and innovation were key to all the positive reviews his business has received so far. The clients are happy to interact and finalize their business faster, while Yakov is happy to expand his business and grow his community.

“Every home tells a story – a place where dreams grow, memories are made, and futures are built,” the agent said.

More information about Yaakov Tannenbaum – Your Brick Expert, the latest listings and prices can be found on the official website.

Media Contact
Company Name: Yaakov Tannenbaum-Your Brick Expert
Contact Person: Yaakov Tannenbaum
Email: Send Email
Phone: 8482457102
Country: United States
Website: http://yaakov.forcepremier.com/

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Expected to rise, 2034 | ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Bioscien

“Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market growth”

The Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market growth is driven by factors like increase in the prevalence of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market report also offers comprehensive insights into the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market size, share, Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market size growth forward.

Some of the key highlights from the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Insights Report:

Several key pharmaceutical companies, including ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno.N Corporation, Jeil Pharmaceutical, Onconic Therapeutics, Plexxikon, Renexxion, Taiho Pharmaceutical, Takeda, Trio Medicines, and others, are developing novel products to improve the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) treatment outlook.
In July 2024, Phathom Pharmaceuticals obtained an expanded indication for its acid suppression medication. The FDA approved the inclusion of heartburn relief associated with non-erosive Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) in Voquezna’s label.
In November 2023, the FDA approved VOQUEZNA (vonoprazan) tablets in 10 mg and 20 mg dosages, a pioneering potassium-competitive acid blocker (PCAB), as a new treatment option for adults. This medication is indicated for healing all grades of Erosive Esophagitis, also known as Erosive GERD, as well as for maintaining healing and relieving heartburn associated with Erosive GERD.
In May 2023, Phathom Pharmaceuticals resubmitted its New Drug Application to the FDA for vonoprazan, seeking approval for the treatment of erosive Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) (GERD), also known as erosive esophagitis.
In June 2022, Zydus Lifesciences received FDA approval to market Famotidine tablets in 20mg and 40mg strengths. Famotidine, a histamine H2 receptor blocker, works by reducing stomach acid and is used to relieve and prevent heartburn and other symptoms of acid reflux.
Several pharmaceutical companies, including Cinclus Pharma, Braintree (part of Sebela Pharmaceuticals), and N-Zyme Biomedical Inc., are actively researching and developing new therapies to meet the unmet needs of GERD patients.
As per DelveInsight analysis, the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Landscape

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Overview

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) (GERD) is a chronic condition in which stomach contents, including acid and bile, flow back into the esophagus, causing symptoms like heartburn, regurgitation, and chest pain. It commonly results from a dysfunction of the lower esophageal sphincter (LES), which typically prevents gastric contents from entering the esophagus. Contributing factors include hiatal hernia, poor esophageal motility, obesity, and certain dietary habits, such as consuming spicy or fatty foods, caffeine, and alcohol. GERD can present as non-erosive reflux disease (NERD), where no visible damage occurs to the esophageal lining, or as erosive esophagitis, which involves inflammation and damage to the esophageal tissue.

Symptoms of GERD can vary in intensity and may include heartburn (a burning sensation in the chest, often aggravated by eating or lying down), regurgitation of acid into the mouth, difficulty swallowing (dysphagia), chest pain, and chronic cough. These symptoms can negatively affect quality of life and may lead to complications such as esophageal strictures, Barrett’s esophagus, and esophageal adenocarcinoma if not treated.

Do you know the treatment paradigms for different countries? Download our Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Sample Report

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Epidemiology Insights

Our analysis shows that the prevalence of GERD in North America ranges from 18% to 28%, while in Europe, it varies from 9% to 26%, indicating a considerable disease burden across both regions.
We also found that females have a higher prevalence of GERD compared to males, suggesting a gender disparity in the occurrence of the condition. This highlights the importance of addressing gender-specific factors in GERD management and treatment. The higher prevalence in females may be due to factors such as hormonal changes, differences in esophageal motility, and anatomical differences.
Additionally, our findings indicate that the age group of 50-59 years has the highest prevalence of GERD, while those aged 70 and above have the lowest. This trend could be linked to age-related changes in gastrointestinal function, lifestyle factors, and the presence of comorbidities in older individuals.

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Epidemiology Segmentation

DelveInsight’s Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) historical patient pools and forecasted Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Prevalence
Age-Specific Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Prevalence
Gender-Specific Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Prevalence
Diagnosed and Treatable Cases of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)

Visit for more @ Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Epidemiological Insights

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Insights:

Several major companies, including Alexion Pharmaceuticals, Novartis, and Roche, are leading the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) (aHUS) treatment landscape. The market details, broken down by country and therapy, are outlined below.
According to DelveInsight’s patient-based forecasting model, the total aHUS market size in the 7MM was approximately USD 1,300 million in 2023, and significant growth is anticipated during the forecast period due to the introduction of new therapies.
In 2023, the United States accounted for the largest share of the aHUS market in the 7MM, approximately 70%, followed by Germany and France.
Among emerging therapies for aHUS, Novartis’ iptacopan and Roche’s crovalimab are expected to play a pivotal role in transforming the market. By 2034, iptacopan is projected to generate the highest revenue among emerging treatments, with nearly USD 100 million expected in the EU4 and the UK.

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Outlook

The management of GERD is divided into five stages: four stages of medical management and one stage involving surgical intervention. The goal of treatment is to reduce esophageal exposure to reflux, alleviate symptoms, heal the esophagus, prevent complications, and maintain remission. Most GERD patients can manage symptoms and promote healing through lifestyle changes and drug therapy without requiring surgery. Surgery is considered for those with severe symptoms, erosive esophagitis, or disease complications despite adequate medication.

Lifestyle changes, such as elevating the head of the bed, reducing fat intake, quitting smoking, limiting alcohol, losing weight, and avoiding large meals and certain foods, are essential throughout treatment.

For mild symptoms, periodic drug therapy is often necessary, using antacids, alginic acid, or over-the-counter H2-receptor blockers. Antacids offer quick symptom relief by neutralizing gastric acid but are not used alone for esophageal healing due to their high dosage requirements. Alginic acid forms a mechanical barrier over the refluxate, protecting the esophagus. H2-receptor blockers provide longer relief, making them more suitable for symptom prevention.

For moderate to severe symptoms, scheduled pharmacologic therapy is required. Proton pump inhibitors (PPIs), such as Dexilant (dexlansoprazole), are used to suppress gastric acid, heal esophagitis, and maintain remission.

Surgery may be needed if medical therapy fails or complications arise, such as large hiatal hernia, Barrett’s esophagus, severe esophagitis, recurrent strictures, or significant pulmonary symptoms. Noncompliance, financial barriers, and relapse of symptoms can also contribute to the need for surgery.

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Marketed Drugs

VOQUEZNA (vonoprazan): Phathom Pharmaceuticals, Inc.

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Emerging Drugs

BLI5100 (Tegoprazan): Braintree/ Sebela Pharmaceuticals

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Key Companies

ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno.N Corporation, Jeil Pharmaceutical, Onconic Therapeutics, Plexxikon, Renexxion, Taiho Pharmaceutical, Takeda, Trio Medicines, and others

For more information, visit Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) epidemiology in the 7MM
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) marketed and emerging therapies
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) companies
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market drivers and barriers

Table of Contents:

1 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Key Comprehensive Insights

2 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Report Introduction

3 Competitive Intelligence Analysis for Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)

4 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Analysis Overview at a Glance

5 Executive Summary of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)

6 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Epidemiology and Market Methodology

7 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Epidemiology and Patient Population

8 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Patient Journey

9 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Treatment Algorithm, Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Current Treatment, and Medical Practices

10 Key Endpoints in Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Clinical Trials

11 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Marketed Therapies

12 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Emerging Therapies

13 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD): 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)

16 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Key Opinion Leaders Reviews

18 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Drivers

19 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Epidemiology 2034

DelveInsight’s “Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Pipeline 2024

“Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market. A detailed picture of the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) pipeline landscape is provided, which includes the disease overview and Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Expected to rise, 2034 | ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Bioscien

Syber Gaming Expands GRVTY Lineup with NVIDIA GeForce RTX 50 Series for Next-Gen Performance

With Nvidia Blackwell chip architecture, Syber GRVTY is a powerhouse for gamers and creators in a monolithic pure-form aesthetic that is an expansion of the M:series design DNA.

Syber, a division of CyberPowerPC, a leader in high-performance gaming and creator PCs, announces the launch of the Syber GRVTY mid-tower gaming PC featuring the latest NVIDIA GeForce RTX 50 Series graphics cards with Blackwell architecture. Engineered for demanding gamers and creators, the GRVTY delivers top-tier performance, a monolithic pure-form design aesthetic, and future-ready technology to redefine the gaming experience.

Powered by NVIDIA GeForce RTX 50 Series graphics, the Syber M GRVTY provides next-generation ray tracing, AI-powered graphics enhancements, and ultra-smooth frame rates at the highest settings. Paired with the latest Intel or AMD processors, this gaming system ensures peak performance for high-resolution gaming, AI-driven experiences, and creative workloads. The chassis design, featuring customizable RGB lighting and enhanced thermal solutions, merges aesthetic appeal with functional innovation, while an optional advanced liquid cooling system maintains optimal temperatures during intense gaming sessions. Designed with longevity in mind, the GRVTY’s upgradeable components allow users to seamlessly adapt to future hardware advancements.

“The launch of the Syber GRVTY in collaboration with NVIDIA represents a significant step forward for gaming performance,” said Eric Cheung, CEO of CyberPowerPC. “This system is the ideal choice for gamers seeking a minimalist aesthetic in a high-performance gaming computer that is hand-crafted and pre-built with the latest hardware.”

The GRVTY is designed for both style and performance. Its sleek, futuristic design ensures it stands out in any setting while maintaining optimal airflow and cooling. Users can personalize the GRVTY with a variety of customization options to meet their specific needs. “The GRVTY is a perfect blend of aesthetics and airflow,” said Tony Crisp, Strategist at Syber. “The Syber GRVTY Core 400 is the most powerful gaming PC the company has ever offered. Gamers will experience firsthand the difference this level of performance provides.

Pricing and Availability

The Syber M GRVTY Core 100 starts at $2,015, with financing options as low as $70 per month with Affirm. The GRVTY lineup includes:

– Syber GRVTY Core 100 – NVIDIA GeForce RTX 4070 + AMD Ryzen

– Syber GRVTY Core 200 – NVIDIA GeForce RTX 4070 + AMD Ryzen

– Syber GRVTY Core 300 – NVIDIA GeForce RTX 5080 + AMD Ryzen

– Syber GRVTY Core 400 – NVIDIA GeForce RTX 5090 + AMD Ryzen

For more details, visit CyberPowerPC.

About Syber

Syber is the product innovation division of CyberPowerPC Inc., launched in 2015. More information is available at Syber Gaming or by contacting Tony Crisp at tony@sybergaming.com.

About CyberPowerPC, Inc.

CyberPowerPC Inc., founded in 1998, is a global provider of custom computer systems and interactive gaming products. Headquartered in Baldwin Park, Southern California, CyberPowerPC manufactures and distributes a complete line of custom-built gaming desktops, gaming notebooks, and high-performance workstations for gamers, businesses, government agencies, and educational institutions.

For more information, contact CyberPowerPC at (800) 707-0393 or cyberpowerpc@cyberpowerpc.com.

Media Contact
Company Name: Syber
Contact Person: Tony Crisp
Email: Send Email
Country: United States
Website: https://www.sybergaming.com/

Personality-Quizzes.com Launches Attachment Style Test Just in Time for Valentine’s Day

Personality-Quizzes.com introduces a science-backed Attachment Style Test, helping individuals understand their relationship patterns ahead of Valentine’s Day.

Personality-Quizzes.com, a leading platform for personality assessments, has launched its new Attachment Style Test, offering users deep insights into their relationship behaviors. Just in time for Valentine’s Day, this test helps individuals explore how they connect with others in romantic and personal relationships.

Attachment theory suggests that people develop different styles of attachment based on early experiences, influencing their interactions in adulthood. The new test at Personality-Quizzes.com categorizes users into secure, anxious, avoidant, or fearful attachment styles, providing them with a clearer understanding of their relationship dynamics.

“Relationships play a crucial role in our emotional well-being, and understanding attachment styles can be a game-changer,” said a spokesperson from Personality-Quizzes.com. “Our test gives users valuable insights into their attachment patterns, empowering them to build healthier connections.”

The Attachment Style Test is designed for accessibility, featuring an intuitive interface that allows users to complete the test quickly and receive immediate results. The results include a breakdown of their attachment style and how it affects their relationships. For those seeking a deeper dive into their relationship patterns, a comprehensive personalized report is available with detailed explanations and actionable insights.

With Valentine’s Day being a time for both reflection and connection, this test provides a timely opportunity for individuals to gain clarity on their emotional needs and relationship behaviors. Whether single, dating, or in a long-term relationship, understanding attachment styles can help individuals cultivate healthier and more fulfilling relationships.

Personality-Quizzes.com has already attracted millions of users with its diverse range of psychology-based assessments. The platform remains committed to providing scientifically supported tools that promote self-awareness, personal growth, and stronger interpersonal relationships.

For more information or to take the attachment style test, visit Personality-Quizzes.com.

About Personality-Quizzes.com

Personality-Quizzes.com is a trusted platform offering a wide range of psychology-based personality assessments. With a mission to enhance self-awareness and personal development, the platform provides users with data-driven insights into various aspects of personality, relationships, and career strengths.

Media Contact
Company Name: Personality Quizzes
Contact Person: Mariana Gomes
Email: Send Email
Country: United States
Website: https://www.personality-quizzes.com/

IsaEnergy Drives Health Revolution in Australia with High-Quality Isagenix Products

IsaEnergy offers a range of unique and high-quality health supplements for health-conscious Australians.

IsaEnergy is a leading online retailer of Isagenix products. The company offers a diverse range of health supplements and aims to serve Australia’s health and wellness needs and help Australians embrace a balanced and nutritious lifestyle.

“As more consumers turn away from fad diets and chemically laden food options, the demand for quality products has been remarkable,” says the spokesperson for IsaEnergy. “Our platform, renowned for its diverse range of premium health supplements, is driving a quiet health revolution in Australia. We have established ourselves as a trusted provider for individuals seeking scientifically backed supplements that promote overall health and well-being.”

The rise in food prices and growing awareness about the importance of nutrition have contributed to the popularity of IsaEnergy’s offerings. Consumers are now more inclined to invest in dietary solutions that are not only cost-effective but also packed with high-quality ingredients.

IsaEnergy’s extensive selection ensures that health-conscious individuals can find products tailored to their specific dietary needs, whether looking for fat-burning solutions, performance enhancement packages, or comprehensive cleansing systems.

IsaEnergy’s customer-centric approach has been a key factor in its success. The company offers features such as a flexible auto-ship program, which allows customers to receive their supplements regularly while maintaining the freedom to cancel anytime. Fast and reliable shipping services enhance the customer experience and ensure prompt order delivery.

The company’s dedication to quality and service excellence has earned it a strong reputation across Australia and New Zealand. IsaEnergy’s commitment to transparency and customer satisfaction is exemplified by its 30-day money-back challenge. First-time users can confidently try the products, knowing that if unsatisfied, they will receive a full refund — even if the product has been used.

IsaEnergy’s collaboration with Isagenix, an internationally renowned brand, underscores its mission to provide top-tier health supplements. Isagenix’s scientifically formulated products support various health goals, from achieving a lean physique to maintaining overall vitality. By offering these trusted solutions, IsaEnergy empowers individuals to make informed choices about their health.

One of IsaEnergy’s standout offerings is the IsaLean range of shakes and meal replacement options. These products are carefully crafted to deliver essential nutrients while being easy to prepare. With growing consumer demand for convenience without compromising nutrition, IsaLean shakes have become popular for those seeking a balanced and healthy diet.

As part of its commitment to fostering a healthier society, IsaEnergy encourages Australians to take proactive steps toward better health. While physical exercise remains a personal responsibility, the company aims to provide comprehensive support through various supplements. The goal is to help individuals achieve their health objectives, whether enhancing performance, supporting healthy aging, or simply maintaining a fit lifestyle.

Looking ahead, IsaEnergy will keep innovating and expanding its offerings to meet the evolving needs of its customers. The company is committed to promoting health and wellness through high-quality products and exceptional customer service.

IsaEnergy invites health-conscious individuals to explore its range of Isagenix products and join the growing community of satisfied customers prioritising their well-being. With a proven track record, fast shipping, and a customer-first approach, IsaEnergy stands out as a leader in the health and wellness sector.

For more information or to place an order, visit https://isaenergy.com.au

About IsaEnergy

Founded in 2017 by Scott Bradbury, IsaEnergy operates throughout Australia and New Zealand, offering a comprehensive range of Isagenix products. These products include lactose-free meal replacement drinks, dairy-free shakes, gluten-free options, and plant-based nutritional solutions. The company has established its reputation as a trusted provider for individuals seeking scientifically-backed supplements that promote overall health and well-being.

Media Contact
Company Name: IsaEnergy Australia
Contact Person: Scott Bradbury
Email: Send Email
Address:Level 2 85 Waterloo Rd
City: Macquarie Park
State: NSW
Country: Australia
Website: https://isaenergy.com.au

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: IsaEnergy Drives Health Revolution in Australia with High-Quality Isagenix Products

Ovarian Cancer Market Expected to rise, 2034 | ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno.N Corporation, Jeil P

“Ovarian Cancer market growth”

The Ovarian Cancer market growth is driven by factors like increase in the prevalence of Ovarian Cancer, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Ovarian Cancer market report also offers comprehensive insights into the Ovarian Cancer market size, share, Ovarian Cancer epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Ovarian Cancer market size growth forward.

Some of the key highlights from the Ovarian Cancer Market Insights Report:

Several key pharmaceutical companies, including ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno.N Corporation, Jeil Pharmaceutical, Onconic Therapeutics, Plexxikon, Renexxion, Taiho Pharmaceutical, Takeda, Trio Medicines, and others, are developing novel products to improve the Ovarian Cancer treatment outlook.
In July 2024, Phathom Pharmaceuticals obtained an expanded indication for its acid suppression medication. The FDA approved the inclusion of heartburn relief associated with non-erosive Ovarian Cancer in Voquezna’s label.
In November 2023, the FDA approved VOQUEZNA (vonoprazan) tablets in 10 mg and 20 mg dosages, a pioneering potassium-competitive acid blocker (PCAB), as a new treatment option for adults. This medication is indicated for healing all grades of Erosive Esophagitis, also known as Erosive GERD, as well as for maintaining healing and relieving heartburn associated with Erosive GERD.
In May 2023, Phathom Pharmaceuticals resubmitted its New Drug Application to the FDA for vonoprazan, seeking approval for the treatment of erosive Ovarian Cancer (GERD), also known as erosive esophagitis.
In June 2022, Zydus Lifesciences received FDA approval to market Famotidine tablets in 20mg and 40mg strengths. Famotidine, a histamine H2 receptor blocker, works by reducing stomach acid and is used to relieve and prevent heartburn and other symptoms of acid reflux.
Several pharmaceutical companies, including Cinclus Pharma, Braintree (part of Sebela Pharmaceuticals), and N-Zyme Biomedical Inc., are actively researching and developing new therapies to meet the unmet needs of GERD patients.
As per DelveInsight analysis, the Ovarian Cancer market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Ovarian Cancer Market Landscape

Ovarian Cancer Overview

Ovarian Cancer (GERD) is a chronic condition in which stomach contents, including acid and bile, flow back into the esophagus, causing symptoms like heartburn, regurgitation, and chest pain. It commonly results from a dysfunction of the lower esophageal sphincter (LES), which typically prevents gastric contents from entering the esophagus. Contributing factors include hiatal hernia, poor esophageal motility, obesity, and certain dietary habits, such as consuming spicy or fatty foods, caffeine, and alcohol. GERD can present as non-erosive reflux disease (NERD), where no visible damage occurs to the esophageal lining, or as erosive esophagitis, which involves inflammation and damage to the esophageal tissue.

Do you know the treatment paradigms for different countries? Download our Ovarian Cancer Market Sample Report

Ovarian Cancer Epidemiology Insights

Our analysis shows that the prevalence of GERD in North America ranges from 18% to 28%, while in Europe, it varies from 9% to 26%, indicating a considerable disease burden across both regions.
We also found that females have a higher prevalence of GERD compared to males, suggesting a gender disparity in the occurrence of the condition. This highlights the importance of addressing gender-specific factors in GERD management and treatment. The higher prevalence in females may be due to factors such as hormonal changes, differences in esophageal motility, and anatomical differences.
Additionally, our findings indicate that the age group of 50-59 years has the highest prevalence of GERD, while those aged 70 and above have the lowest. This trend could be linked to age-related changes in gastrointestinal function, lifestyle factors, and the presence of comorbidities in older individuals.

Ovarian Cancer Epidemiology Segmentation

DelveInsight’s Ovarian Cancer market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Ovarian Cancer historical patient pools and forecasted Ovarian Cancer patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Ovarian Cancer Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

Ovarian Cancer Prevalence
Age-Specific Ovarian Cancer Prevalence
Gender-Specific Ovarian Cancer Prevalence
Diagnosed and Treatable Cases of Ovarian Cancer

Visit for more @ Ovarian Cancer Epidemiological Insights

Ovarian Cancer Market Insights:

Several major companies, including Alexion Pharmaceuticals, Novartis, and Roche, are leading the Ovarian Cancer (aHUS) treatment landscape. The market details, broken down by country and therapy, are outlined below.
According to DelveInsight’s patient-based forecasting model, the total aHUS market size in the 7MM was approximately USD 1,300 million in 2023, and significant growth is anticipated during the forecast period due to the introduction of new therapies.
In 2023, the United States accounted for the largest share of the aHUS market in the 7MM, approximately 70%, followed by Germany and France.
Among emerging therapies for aHUS, Novartis’ iptacopan and Roche’s crovalimab are expected to play a pivotal role in transforming the market. By 2034, iptacopan is projected to generate the highest revenue among emerging treatments, with nearly USD 100 million expected in the EU4 and the UK.

Ovarian Cancer Market Outlook

Ovarian Cancer Marketed Drugs

VOQUEZNA (vonoprazan): Phathom Pharmaceuticals, Inc.

Ovarian Cancer Emerging Drugs

BLI5100 (Tegoprazan): Braintree/ Sebela Pharmaceuticals

Ovarian Cancer Key Companies

ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno.N Corporation, Jeil Pharmaceutical, Onconic Therapeutics, Plexxikon, Renexxion, Taiho Pharmaceutical, Takeda, Trio Medicines, and others

For more information, visit Ovarian Cancer Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Ovarian Cancer Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Ovarian Cancer, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Ovarian Cancer epidemiology in the 7MM
Ovarian Cancer marketed and emerging therapies
Ovarian Cancer companies
Ovarian Cancer market drivers and barriers

Table of Contents:

1 Ovarian Cancer Market Key Comprehensive Insights

2 Ovarian Cancer Market Report Introduction

3 Competitive Intelligence Analysis for Ovarian Cancer

4 Ovarian Cancer Market Analysis Overview at a Glance

5 Executive Summary of Ovarian Cancer

6 Ovarian Cancer Epidemiology and Market Methodology

7 Ovarian Cancer Epidemiology and Patient Population

8 Ovarian Cancer Patient Journey

9 Ovarian Cancer Treatment Algorithm, Ovarian Cancer Current Treatment, and Medical Practices

10 Key Endpoints in Ovarian Cancer Clinical Trials

11 Ovarian Cancer Marketed Therapies

12 Ovarian Cancer Emerging Therapies

13 Ovarian Cancer: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Ovarian Cancer

16 Ovarian Cancer Market Key Opinion Leaders Reviews

18 Ovarian Cancer Market Drivers

19 Ovarian Cancer Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Ovarian Cancer Epidemiology 2034

DelveInsight’s “Ovarian Cancer – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Ovarian Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Ovarian Cancer Pipeline 2024

“Ovarian Cancer Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Ovarian Cancer market. A detailed picture of the Ovarian Cancer pipeline landscape is provided, which includes the disease overview and Ovarian Cancer treatment guidelines.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ovarian Cancer Market Expected to rise, 2034 | ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno.N Corporation, Jeil P

Experience the Future of Game Nights: Make a Break Presents Dunkelstein, Their Latest Spellbinding AR Tabletop Adventure for Mystery Lovers of All Ages

Dunkelstein, the latest innovation from Make a Break, is officially set to launch on Kickstarter, inviting backers to experience the future of game nights. Blending the nostalgic charm of board games with state-of-the-art augmented reality (AR), Dunkelstein transforms any table into the site of an intricate murder mystery set in 1914 Germany.

Players step into the shoes of Helene, a detective on a mission to prove her innocence, as they unravel the secrets of a meticulously crafted villa. Guided by clues hidden within each room and challenged by interactive puzzles, players must piece together evidence and outsmart the real villain before time runs out.

With every decision impacting Helene’s fate, Dunkelstein offers multiple story paths, twists, and outcomes, rewarding both critical thinking and teamwork. Dunkelstein introduces a new era of tabletop gaming, combining captivating storytelling, player interaction, and immersive visuals through mixed-reality technology.

“With Dunkelstein, our aim is to blend social interaction with cutting-edge technology, creating an experience that feels modern yet classic,” said Zoltan Ferenczi, CEO of Make a Break. “Players can expect a deeply engaging story, lifelike characters, and the sense of mystery that makes for an unforgettable game night.”

From Escape Rooms to Augmented Reality: A Legacy of Immersive Gaming

Make a Break has a proud history in the live escape game industry, known for designing captivating and thrilling experiences that challenge players to think critically under pressure. As the world of gaming evolves, the company is now shifting its focus to the exciting frontier of augmented reality (AR) games. Dunkelstein represents this evolution, offering a unique blend of physical and digital worlds that builds on Make a Break’s legacy of creating deeply immersive, social gaming experiences.

Key Features of Dunkelstein Include:

Immersive Augmented Reality: Players watch as the Dunkelstein villa springs to life with animated scenes and engaging characters, all rendered in exquisite detail using Unreal Engine technology and accessible with just mobile devices.
High-Quality Craftsmanship: Available in two editions, the Deluxe Villa Board Set and the Essential Flat Playboard, Dunkelstein’s game boards are crafted from durable wood, ensuring a sustainable, reusable experience that withstands repeated play.
Endlessly Replayable: With its branching-paths storyline and multiple endings, Dunkelstein is designed for 2-4 players, offering a fresh, memorable experience each time. Perfect for game nights, date nights, and family gatherings.
Cutting-Edge Technology Integration: Dunkelstein leverages motion capture and interactive storytelling to create a seamless blend between the physical and digital worlds, making it one of the first of its kind in the tabletop gaming space.

Shaping the Future of Tabletop Games with Augmented Reality

Make a Break, founded in Berlin, is dedicated to pioneering augmented reality experiences that bring together physical and digital worlds for immersive, social gameplay. With extensive experience in both game development and XR technologies, Make a Break aims to push the boundaries of traditional game nights.

The Kickstarter campaign allows early supporters exclusive access to the Deluxe Villa model and discounted pledge tiers, along with the opportunity to participate in future storyline developments. Dunkelstein’s backers will play a crucial role in bringing this unique vision to life, contributing to a growing community centered around innovative and social gaming experiences.

For more information about the project, or to back their Kickstarter, visit Make a Break’s Dunkelstein page at https://www.kickstarter.com/projects/1598131183/dunkelstein

Media Contact
Company Name: Make a Break
City: Berlin
Country: Germany
Website: www.kickstarter.com/projects/1598131183/dunkelstein?ref=e91mpc

Activism in Every Art Piece: Smallfry’s ‘Museum of Modern Life’ Debuts in Amsterdam

Smallfry, a contemporary art initiative by the duo of Dutch artists Fraser Small and Roëll Wahle, officially announces the launch of its Kickstarter campaign for the Museum of Modern Life. This new attraction promises to blend captivating artworks with impactful social and environmental commentary, inviting visitors to engage in an experience where art inspires change.

Set against the vibrant backdrop of Amsterdam, the Museum of Modern Life aims to provide an interactive journey through thought-provoking exhibits. From installations like “The Social Butterfly,” critiquing environmental policies, to “One Day My Son, This Will All Be Yours,” highlighting consumerism’s legacy, each piece is designed to spark conversation and inspire action. Smallfry’s work, known for its bright visuals with deep narratives, creates a platform where visitors not only witness art but become part of its story.

In a remarkable achievement, Smallfry was recently invited to showcase two of their pieces at the World Economic Forum in Davos—a prestigious event where world leaders gather to address global challenges. This recognition highlights the growing impact and relevance of Smallfry’s work in bridging art with positive activism.

“With the Museum of Modern Life, we’re building more than just an art space—we’re creating a brand for change,” said Fraser Small. “Our installations allow visitors to actively engage, learn, and contribute, all while experiencing visually stunning pieces that resonate with today’s social and environmental challenges.”

Key Highlights of the Museum:

Immersive Art Installations: Visitors will experience multi-sensory exhibits that encourage interaction and personal involvement, transforming spectators into participants.
Environmental and Social Narratives: Each exhibit tells a compelling story, urging reflection on issues such as climate change, consumerism, and capitalism through powerful visual metaphors.
Charitable Impact: A significant portion of ticket sales—starting at 20% and increasing annually—will be donated to causes aligned with the themes explored in the art.
Insta-Worthy Displays: Selfies and photos are encouraged so visitors won’t just be able to enjoy the art, but also spread meaningful and captivating messages to the world beyond the museum.

“Our vision is to make the Museum of Modern Life a space where art, social commentary, and community converge. We’re excited to involve our supporters through Kickstarter, offering them exclusive rewards and the chance to be part of something transformative,” added Roëll Wahle.

Supporters of the Kickstarter campaign will receive access to limited-edition artworks, clothing, signed coffee-table books, and the chance to have their names featured within the museum.

For more information or to support the campaign, visit their Kickstarter page at https://www.kickstarter.com/projects/1099222210/smallfrys-museum-of-modern-life

Media Contact
Company Name: Smallfry: Museum of Modern Life
City: Amsterdam
Country: Netherlands
Website: www.kickstarter.com/projects/1099222210/smallfrys-museum-of-modern-life?ref=wj85z9

Myotonic dystrophy Market Expected to rise, 2034 | Lupin, AMO Pharma Limited, Harmony Biosciences, LLC, expected to drive market

“Myotonic dystrophy market growth”

The Myotonic dystrophy market growth is driven by factors like increase in the prevalence of Myotonic dystrophy, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Myotonic dystrophy market report also offers comprehensive insights into the Myotonic dystrophy market size, share, Myotonic dystrophy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Myotonic dystrophy market size growth forward.

Recent breakthroughs in the myotonic dystrophy market are:

December 2024 Updates:

PepGen Inc.: A study is underway to assess the effects of the investigational drug PGN-EDODM1, focusing on the safety and tolerability of multiple administrations of PGN-EDODM1 in individuals with myotonic dystrophy type 1 (DM1) compared to a placebo.
Avidity Biosciences Inc.: A clinical trial is being conducted with a 6-week screening period followed by a 54-week treatment phase, totaling approximately 60 weeks. Participants are randomized to receive intravenous infusions of either del-desiran or a placebo at 8-week intervals for a total of seven doses. The final dose is scheduled for Week 48, with the last assessment at Week 54.
Vertex Pharmaceuticals: A Phase 1/2 study is underway to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 in adults with DM1. The trial is randomized, double-blind, and placebo-controlled, involving both single- and multiple-dose escalations.

November 2024 Update:

ARTHEx Biotech S.L.: The FDA has granted Rare Pediatric Disease Designation (RPD) to ATX-01 for the treatment of myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder. This designation follows the earlier Orphan Drug Designation (ODD) granted by U.S. and European regulatory authorities.

Some of the key highlights from the Myotonic dystrophy Market Insights Report:

Several key pharmaceutical companies, including Lupin, AMO Pharma Limited, Harmony Biosciences, LLC, and others, are developing novel products to improve the Myotonic dystrophy treatment outlook.
The Myotonic Dystrophy market is expected to experience steady growth throughout the forecast period (2024–2034). In the seven major markets (7MM), the Myotonic Dystrophy treatment market size is projected to expand, driven by improved diagnostic capabilities and the introduction of new therapies.
According to DelveInsight’s analysis, approximately 51% of the diagnosed prevalent Myotonic Dystrophy cases in the 7MM are in the United States. In 2023, the U.S. accounted for an estimated 54,068 diagnosed cases of Myotonic Dystrophy. The total treatment market is anticipated to grow further during the forecast period, supported by the development and potential approval of emerging therapies such as Tideglusib (AMO-02).
The Myotonic Dystrophy therapeutics market is forecasted to grow at a significant compound annual growth rate (CAGR) of 18.4% from 2020 to 2034. This substantial growth reflects increasing demand for advanced treatment options and highlights rising investments in addressing this challenging condition.
Several factors contribute to this growth, including the rising prevalence of genetic disorders, increased awareness of rare diseases, advancements in genomic research, and growing investment in rare disease therapies. However, challenges such as limited research funding, high costs associated with innovative treatments, and stringent regulatory requirements pose significant barriers. Additionally, the unmet need for effective Myotonic Dystrophy treatments underscores a critical gap in the current therapeutic landscape, presenting opportunities for innovation to meet the needs of a diverse patient population.
As per DelveInsight analysis, the Myotonic dystrophy market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Myotonic dystrophy Market Landscape

Myotonic dystrophy Overview

Myotonic dystrophy types 1 and 2 are among the most prevalent forms of muscular dystrophy that typically present during adulthood. Recognizing the clinical distinctions between these two types is critical for selecting the most suitable treatment approaches for patients. While no disease-modifying therapies currently exist, various symptomatic treatments are available to help manage the condition. Encouragingly, advancements in next-generation therapies may soon offer new possibilities for individuals affected by the disease. Effective symptom management is vital, as it can greatly alleviate patient suffering and improve overall quality of life. Additionally, regular disease monitoring is essential to detect and address potential complications during critical periods.

Myotonic dystrophy is a type of muscular dystrophy, a group of disorders marked by the weakening and degeneration of specific voluntary muscles in the body. Each form of muscular dystrophy has unique characteristics, including variations in muscle fiber size, muscle fiber necrosis, scar tissue formation, and inflammation, as observed in muscle biopsies from affected patients.

There are two main types of myotonic dystrophy: type 1 (commonly known as Steinert disease, after Dr. Steinert who first described it in 1909) and type 2 (referred to as Ricker syndrome or proximal myotonic dystrophy, PROMM). Myotonic dystrophy should be suspected in patients presenting with muscle weakness, a family history of the condition, and characteristic physical exam findings.

The gold standard for diagnosing myotonic dystrophy is genetic testing for CTG repeat expansions. Additional diagnostic tests may include serum creatine kinase levels, hepatobiliary function tests, muscle biopsies, and electrocardiograms to evaluate potential cardiomyopathy. These tests are often performed before genetic confirmation to assess the overall impact of the disease on the patient’s health.

Do you know the treatment paradigms for different countries? Download our Myotonic dystrophy Market Sample Report

Myotonic dystrophy Epidemiology Insights

Within the 7MM, the EU4 and the UK collectively accounted for approximately 353,191 diagnosed prevalent cases of myotonic dystrophy, with this number projected to grow during the forecast period (2024–2034).
Among the EU4 and the UK, Germany had the highest diagnosed prevalence of myotonic dystrophy in 2023, with 8,938 cases, followed by the UK and France. Conversely, Spain had the lowest diagnosed prevalence within this group.
In Japan, there were approximately 12,735 diagnosed prevalent cases of myotonic dystrophy in 2023, and this number is anticipated to grow at a notable CAGR.

Myotonic dystrophy Epidemiology Segmentation

DelveInsight’s Myotonic dystrophy market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Myotonic dystrophy historical patient pools and forecasted Myotonic dystrophy patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Myotonic dystrophy Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

Myotonic dystrophy Prevalence
Age-Specific Myotonic dystrophy Prevalence
Gender-Specific Myotonic dystrophy Prevalence
Diagnosed and Treatable Cases of Myotonic dystrophy

Visit for more @ Myotonic dystrophy Epidemiological Insights

Myotonic dystrophy Market Outlook

Myotonic dystrophy is a dominantly inherited form of muscular dystrophy that impacts both muscles and various body systems. It can cause symptoms such as early cataracts, myotonia, muscle weakness and atrophy, fatigue, excessive daytime sleepiness, central or obstructive apnea, respiratory failure, cardiac arrhythmias, insulin resistance, dysphagia, mood disorders, and more.

There are two types of myotonic dystrophy:

– Type 1 (DM1): Caused by the expansion of a CTG triplet repeat in the DMPK gene.

– Type 2 (DM2): Caused by the expansion of a CCTG tetramer repeat in the CNBP gene.

The symptoms of DM2 are generally milder than those of DM1 and lack a congenital form. Clinical manifestations of DM2 typically begin after the third decade of life, presenting with muscle-related symptoms such as weakness, musculoskeletal pain, stiffness, myotonia, fatigue, and exercise intolerance, which are often the reasons for initial neurological referrals. It is essential to adopt tailored interventions to improve patients’ quality of life (QoL).

Currently, no therapies are approved to cure or slow the progression of myotonic dystrophy. However, symptomatic treatments are available to alleviate suffering and enhance QoL.

Symptom Management:

– Myotonia: The most commonly treated symptom, managed with off-label antimyotonic agents such as mexiletine, lamotrigine, carbamazepine, oxcarbazepine, flecainide, propafenone, phenytoin, and ranolazine.

– Chronic Muscle Pain: Managed using the WHO four-step ladder for pain management, beginning with NSAIDs. Additional therapies may include anticonvulsants (pregabalin, gabapentin), antidepressants (duloxetine, amitriptyline, nortriptyline), muscle relaxants (baclofen, tizanidine), or topical agents (lidocaine or capsaicin patches).

– Excessive Daytime Sleepiness: More prevalent in DM1 and managed with medications like methylphenidate and modafinil, which are well-tolerated and effective.

– Diabetic Symptoms: Managed with anti-diabetic drugs like metformin to normalize blood sugar levels.

Additionally, various medications, rehabilitative therapies, surgeries, and medical devices are used to address symptoms and complications.

Emerging Therapies:

Mexiletine, currently used off-label, is under development for formal approval and is in the pipeline for myotonic dystrophy treatment. This underscores its potential efficacy and highlights the need for its recognition as an authorized therapy in regions such as the US, the EU, and Japan.

Myotonic dystrophy Emerging Drugs

Tideglusib (AMO-02): AMO Pharma
Delpacibart etedesiran (AOC-1001): Avidity Biosciences, Inc.

Myotonic dystrophy Key Companies

Lupin, AMO Pharma Limited, Harmony Biosciences, LLC, and others

For more information, visit Myotonic dystrophy Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Myotonic dystrophy Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Myotonic dystrophy, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Myotonic dystrophy epidemiology in the 7MM
Myotonic dystrophy marketed and emerging therapies
Myotonic dystrophy companies
Myotonic dystrophy market drivers and barriers

Table of Contents:

1 Myotonic dystrophy Market Key Comprehensive Insights

2 Myotonic dystrophy Market Report Introduction

3 Competitive Intelligence Analysis for Myotonic dystrophy

4 Myotonic dystrophy Market Analysis Overview at a Glance

5 Executive Summary of Myotonic dystrophy

6 Myotonic dystrophy Epidemiology and Market Methodology

7 Myotonic dystrophy Epidemiology and Patient Population

8 Myotonic dystrophy Patient Journey

9 Myotonic dystrophy Treatment Algorithm, Myotonic dystrophy Current Treatment, and Medical Practices

10 Key Endpoints in Myotonic dystrophy Clinical Trials

11 Myotonic dystrophy Marketed Therapies

12 Myotonic dystrophy Emerging Therapies

13 Myotonic dystrophy: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Myotonic dystrophy

16 Myotonic dystrophy Market Key Opinion Leaders Reviews

18 Myotonic dystrophy Market Drivers

19 Myotonic dystrophy Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Myotonic dystrophy Epidemiology 2034

DelveInsight’s “Myotonic dystrophy – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Myotonic dystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Myotonic dystrophy Pipeline 2024

“Myotonic dystrophy Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Myotonic dystrophy market. A detailed picture of the Myotonic dystrophy pipeline landscape is provided, which includes the disease overview and Myotonic dystrophy treatment guidelines.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myotonic dystrophy Market Expected to rise, 2034 | Lupin, AMO Pharma Limited, Harmony Biosciences, LLC, expected to drive market

The Therapeutic Couch Offers Truly Inclusive and Culturally-Sensitive Therapeutic Environment, Extends Free 15-Minute Consultations to Anyone Interested in Therapy

The Therapeutic Couch is a Canadian therapy practice focused on clients from all cultural and religious backgrounds.

The Therapeutic Couch, a team of Canadian registered psychotherapists, has extended an open invitation to anyone interested to book a free 15-minute consultation.

Led by founder Alia Siddiqi, the team of four has worked hard to create a therapeutic environment that is genuinely inclusive, diverse, and culturally sensitive.

The team has explained that their ultimate mission was providing a space “that intuitively understands and respects your unique cultural and religious backgrounds, so you can focus on your healing journey without the burden of over-explaining the nuances of your identity.”

This way, the services of The Therapeutic Couch are tailored to meet the needs of every single client while “embracing and celebrating the rich tapestry of human experiences.”

“We believe in the power of understanding and empathy, and our team is trained to approach every session with cultural competence and profound respect for your personal narrative,” the team stated.

Beyond consultations, the list of therapeutic services the company offers includes individual therapy, couples therapy, as well as options for online sessions.

Beyond Alia, the Thearapeutic Couch team consists of Registered Psychotherapists Rida Ahman, Maryum Rahman, and Sukhmeet Brar.

In Siddiqi’s own works, the team embraces her original decision of “creating a enviorement that addresses the diverse needs of our community through compassionate, evidence-based, and culturally sensitive therapeutic practices.”

“On the surface, it may feel like we do not have the strength to get through these hardships. But I believe that we can find it within ourselves to forge new pathways towards happiness,” the therapist stated, adding, “Therapy is empowering! By working through emotions, thoughts, and feelings, you can grow into the person you want to be, and achieve your full potential.”

The Therapeutic Couch also hosts a free blog with valuable resources on mental health topics. More information about the company, the team, and the latest rates, can be found on the official website.

Media Contact
Company Name: The Therapy Couch
Contact Person: Alia Siddiqi
Email: Send Email
Country: Canada
Website: https://www.therapycouch.ca/